Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Intellia Thera CS (NTLA)

Intellia Thera CS (NTLA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,379,535
  • Shares Outstanding, K 115,830
  • Annual Sales, $ 57,880 K
  • Annual Income, $ -519,020 K
  • EBIT $ -479 M
  • EBITDA $ -468 M
  • 60-Month Beta 2.10
  • Price/Sales 21.69
  • Price/Cash Flow N/A
  • Price/Book 1.79

Options Overview Details

View History
  • Implied Volatility 98.17% (+5.33%)
  • Historical Volatility 86.71%
  • IV Percentile 81%
  • IV Rank 32.55%
  • IV High 154.61% on 10/27/25
  • IV Low 70.94% on 08/20/25
  • Expected Move (DTE 9) 1.33 (11.12%)
  • Put/Call Vol Ratio 0.50
  • Today's Volume 415
  • Volume Avg (30-Day) 5,613
  • Put/Call OI Ratio 0.30
  • Today's Open Interest 110,303
  • Open Int (30-Day) 106,988
  • Expected Range 10.67 to 13.33

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 26 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.99
  • Number of Estimates 10
  • High Estimate -0.89
  • Low Estimate -1.10
  • Prior Year -1.24
  • Growth Rate Est. (year over year) +20.16%

Price Performance

See More
Period Period Low Period High Performance
1-Month
10.15 +18.28%
on 01/12/26
17.09 -29.78%
on 01/27/26
+1.62 (+15.61%)
since 01/09/26
3-Month
7.95 +50.94%
on 11/21/25
17.09 -29.78%
on 01/27/26
+1.82 (+17.88%)
since 11/11/25
52-Week
5.90 +103.39%
on 04/07/25
28.25 -57.52%
on 10/20/25
+2.79 (+30.29%)
since 02/11/25

Most Recent Stories

More News
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies,...

NTLA : 12.00 (+0.76%)
Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE-2 Phase 3 Clinical Trial in ATTRv-PN

Plan to resume MAGNITUDE-2 patient enrollment and dosing FDA engagement ongoing regarding clinical hold on MAGNITUDE Phase 3 clinical trial in ATTR-CM CAMBRIDGE, Mass., Jan. 27, 2026 (GLOBE...

NTLA : 12.00 (+0.76%)
Intellia Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies,...

NTLA : 12.00 (+0.76%)
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Jan. 02, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies,...

NTLA : 12.00 (+0.76%)
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Dec. 05, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies,...

NTLA : 12.00 (+0.76%)
Longevity-Focused Health Fueling U.S. Anti-Aging Products Market Projected to Reach $27 Billion By 2033

EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:RXRX),(NASDAQ:NTLA),(NASDAQ:ZYME),(NYSE:ANVS) EQNX::TICKER_END

AVAI : 0.3822 (+0.82%)
ANVS : 2.37 (-1.25%)
RXRX : 3.71 (-3.64%)
ZYME : 22.83 (+0.44%)
NTLA : 12.00 (+0.76%)
Longevity-Focused Health Fueling U.S. Anti-Aging Products Market Projected to Reach $27 Billion By 2033

MarketNewsUpdates News Commentary NEW YORK, Nov. 18, 2025 (GLOBE NEWSWIRE) -- The advance anti-aging therapies market is expanding quickly fueled by a larger senior population and increased...

AVAI : 0.3822 (+0.82%)
ANVS : 2.37 (-1.25%)
RXRX : 3.71 (-3.64%)
ZYME : 22.83 (+0.44%)
NTLA : 12.00 (+0.76%)
Should You Buy the Dip in Intellia Therapeutics Stock?

A patient’s death shook Intellia Therapeutics and sank its stock. Should investors buy the dip or steer clear?

SRPT : 17.96 (-2.02%)
REGN : 778.97 (+3.19%)
PFE : 27.73 (+0.43%)
NTLA : 12.00 (+0.76%)
Is This Beaten-Down Cathie Wood Stock Still a Buy?

Intellia’s shares plunged 23% after its Q3 results showed a pipeline setback. Nonetheless, Cathie Wood’s stake in the company is expanding.

NTLA : 12.00 (+0.76%)
ARKK : 70.87 (-1.92%)
Intellia Therapeutics Presents Positive Longer-Term Phase 1 Data of Nexiguran Ziclumeran (nex-z) in Patients with Transthyretin (ATTR) Amyloidosis with Cardiomyopathy

One-time treatment of nex-z led to consistently rapid, deep and durable reduction in serum TTR through three years of follow-up Consistent trend in disease stability or improvement in multiple measures...

NTLA : 12.00 (+0.76%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Intellia Therapeutics is a leading clinical-stage genome editing company focused on developing CRISPR/Cas9-based therapeutics. The company is pursuing two primary approaches to fully realize the transformative potential of CRISPR/Cas9 in vivo programs that use intravenously administered CRISPR as the...

See More

Key Turning Points

3rd Resistance Point 12.92
2nd Resistance Point 12.48
1st Resistance Point 12.24
Last Price 12.00
1st Support Level 11.56
2nd Support Level 11.12
3rd Support Level 10.88

See More

52-Week High 28.25
Fibonacci 61.8% 19.71
Fibonacci 50% 17.08
Fibonacci 38.2% 14.44
Last Price 12.00
52-Week Low 5.90

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar